Report copyright - NOVEL TARGETS/THERAPIES PROTEASOME INHIBITORS · NPI-0052 Irreversible inhibitor Early phase I testing Bortezomib Reversible inhibitor Approved for MCL Carfilzomib(PR-171) Irreversible
Please pass captcha verification before submit form